Search company, investor...

Radiance Therapeutics

Submit Your Analyst Briefing

radiancetherapeutics.com

Founded Year

2018

Stage

Debt - II | Alive

Total Raised

$14.01M

Last Raised

$4.29M | 2 yrs ago

About Radiance Therapeutics

Radiance Therapeutics is commercializing a clinically demonstrated anti-metabolite therapy for glaucoma drainage surgery. Its Beta Ophthalmic System is designed to apply beta therapy to the surgical site to down-regulate fibroblasts that cause scar tissue, keeping the channel open and maintaining reduced intraocular pressure.

Headquarters Location

7440 N Oracle Rd Bldg 1

Tucson, Arizona, 8570,

United States

Missing: Radiance Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Radiance Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Radiance Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Radiance Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Radiance Therapeutics Patents

Radiance Therapeutics has filed 7 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Ophthalmology
  • Radioactivity
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/27/2019

3/15/2022

Diseases of the eye and adnexa, Radiation therapy, Radioactivity, Radiobiology, Ophthalmology

Grant

Application Date

11/27/2019

Grant Date

3/15/2022

Title

Related Topics

Diseases of the eye and adnexa, Radiation therapy, Radioactivity, Radiobiology, Ophthalmology

Status

Grant

Latest Radiance Therapeutics News

RadianceTx® Expands Team to Develop Beta Ophthalmic System

Apr 29, 2019

0 Message : *Required fields Radiance Therapeutics, Inc. (RadianceTx®) is pleased to announce the expansion of its core team: Abigail Mackrill, formerly of Ophthalmology Futures Forums and The Ophthalmologist, joins as Director of Business Development and Outreach. James Fazio, MBA, Msc Eng, formerly Global Business Leader for Gore Medical’s Peripheral Vascular business unit, will now serve as Director of Engineering at RadianceTx®. Cassie Vollmer, Director of Quality Assurance and Regulatory Affairs, joins RadianceTx® from Vyaire Medical. Ms Mackrill, Mr Fazio, and Ms Vollmer join the growing RadianceTx® team lead by Chief Executive Officer, Laurence Marsteller MD and President and Chief Financial Officer, Harry George, to drive RadianceTx® through its next phase of development. The RadianceTx® Beta Ophthalmic System is a device solution designed for topical application of beta therapy, currently under development. Dr Marsteller comments “Radiance Therapeutics’ successful recruitment of commercial leaders to our team is due in large part to the exciting opportunity our device presents as a tool that can help ophthalmologists improve surgical outcomes.” RadianceTx® Board member Marc Sandroff, Founder and Principal at Cadre Partners, an investor in Radiance Therapeutics, Inc., and formerly Managing Director of Essex Woodlands Health Venture Funds states: “We have seen the compelling clinical data and strongly support the vision of the leadership team to address this vital therapeutic unmet need. We look forward to our coming achievements together.” Validated in three clinical studies conducted by preeminent ophthalmic research teams utilizing legacy devices, beta therapy has been shown to reduce post-operative scarring and therefore improve glaucoma filtration surgery outcomes [1,2]. A recent study reported odds ratios that beta therapy patients were five and a half times more likely to experience lower IOP at the end of one year than patients treated with the current standard of care, Mitomycin-C [3]. Sir Peng Khaw, Consultant Ophthalmic Surgeon and Professor of Glaucoma Studies and Wound Healing, and member of the Board of Directors at RadianceTx® states “for glaucoma surgery to be maximally successful, anti-scarring therapies must be effective, consistent in dosage as well as fast and very easy to administer. In combination with new glaucoma drainage devices, beta therapy could revolutionize the treatment of glaucoma.” 1. Kirwan, JF et al. Effect of Beta Radiation on Success of Glaucoma Drainage Surgery in South Africa: Randomised Controlled Trial. BMJ, doi:10.1136/bmj.38971.395301.7C (published 5 October 2006) 2. Dhalla, K et al. Is Beta Radiation Better than 5 Flurouracil as an Adjunct for Trabeculectomy Surgery When Combined with Cataract Surgery? A Randomized Controlled Trial. PloS ONE 11(9) 3.Cook, C et al. Randomised Clinical Trial of Trabeculectomy with Mitomycin-C Versus Trabeculectomy with Beta Radiation. South African Ophthalmology Journal, 13, 11-14 (2018) About RadianceTx® RadianceTx® is a trademark of Radiance Therapeutics, Inc., a Delaware corporation. Radiance Therapeutics, Inc., is developing a next-generation beta ophthalmic applicator. For more information visit www.radiancetherapeutics.com CAUTION Investigational device. Limited by United States law to investigational use. View source version on businesswire.com: https://www.businesswire.com/news/home/20190429005712/en/ © Business Wire 2019

Radiance Therapeutics Frequently Asked Questions (FAQ)

  • When was Radiance Therapeutics founded?

    Radiance Therapeutics was founded in 2018.

  • Where is Radiance Therapeutics's headquarters?

    Radiance Therapeutics's headquarters is located at 7440 N Oracle Rd, Tucson.

  • What is Radiance Therapeutics's latest funding round?

    Radiance Therapeutics's latest funding round is Debt - II.

  • How much did Radiance Therapeutics raise?

    Radiance Therapeutics raised a total of $14.01M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.